Payment overview · 2025
General Payments
$278.11
14 reported records · 6 companies
Healthcare provider profile · identity verified
Michael S. Huber, M.D.
Allopathic & Osteopathic Physicians|Family Medicine · LUCEDALE, MS · NPI 1487767281
Verified facts
What the public records show
CMS Open Payments records show Michael S. Huber, M.D. received $278.11 in general payments during 2025 across 14 reported records.
Salix Pharmaceuticals, a division of Bausch Health US, LLC accounted for 30.9% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 6 associated products.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Ozempic as an associated drug or biological on 261625 records involving 77793 distinct recipient NPIs. Public Medicare Part D data also shows 105 claims for Ozempic by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Rybelsus as an associated drug or biological on 161257 records involving 55409 distinct recipient NPIs. Public Medicare Part D data also shows 14 claims for Rybelsus by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Tresiba as an associated drug or biological on 415 records involving 264 distinct recipient NPIs. Public Medicare Part D data also shows 13 claims for Tresiba by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| Salix Pharmaceuticals, a division of Bausch Health US, LLC | Unresolved — no canonical attribution shown | $85.83 | 30.9% | 4 | 2025 |
| Novo Nordisk Inc | Unresolved — no canonical attribution shown | $69.54 | 25.0% | 4 | 2025 |
| Otsuka America Pharmaceutical, Inc. | Unresolved — no canonical attribution shown | $67.59 | 24.3% | 3 | 2025 |
| Amgen Inc. | Unresolved — no canonical attribution shown | $19.26 | 6.9% | 1 | 2025 |
| Axsome Therapeutics, Inc. | Unresolved — no canonical attribution shown | $18.51 | 6.7% | 1 | 2025 |
| Paratek Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $17.38 | 6.2% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $278.11 | 14 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| XIFAXAN Normalized: xifaxan |
Drug | Salix Pharmaceuticals, a division of Bausch Health US, LLC | $85.83 | 4 | 2025 |
Source payment records
|
|||||
| REXULTI Normalized: rexulti |
Drug | Otsuka America Pharmaceutical, Inc. | $67.59 | 3 | 2025 |
Source payment records
|
|||||
| Wegovy Normalized: wegovy |
Drug | Novo Nordisk Inc | $25.58 | 1 | 2025 |
Source payment records
|
|||||
| EVENITY Normalized: evenity |
Biological | Amgen Inc. | $19.26 | 1 | 2025 |
Source payment records
|
|||||
| Sunosi Normalized: sunosi |
Drug | Axsome Therapeutics, Inc. | $18.51 | 1 | 2025 |
Source payment records
|
|||||
| NUZYRA Normalized: nuzyra |
Drug | Paratek Pharmaceuticals, Inc. | $17.38 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
No exact normalized or approved-alias overlap was found in the loaded Part D year. This does not mean the doctor never prescribed the product.
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Ozempic open payments reported associated product |
CMS Open Payments — General Payments 261625 supporting records · 77793 recipient NPIs · example record 1188130076 |
Ozempic · 2024 Exact normalized brand match · 1 Part D row |
105 | 20 |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Rybelsus open payments reported associated product |
CMS Open Payments — General Payments 161257 supporting records · 55409 recipient NPIs · example record 1188130076 |
Rybelsus · 2024 Exact normalized brand match · 1 Part D row |
14 | suppressed by CMS |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Tresiba open payments reported associated product |
CMS Open Payments — General Payments 415 supporting records · 264 recipient NPIs · example record 1188130328 |
Tresiba · 2024 Exact normalized brand match · 1 Part D row |
13 | suppressed by CMS |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Hydrocodone-Acetaminophen | Hydrocodone/Acetaminophen | 959 | 114 |
| Gabapentin | Gabapentin | 735 | 128 |
| Pantoprazole Sodium | Pantoprazole Sodium | 679 | 132 |
| Potassium Chloride | Potassium Chloride | 569 | 112 |
| Atorvastatin Calcium | Atorvastatin Calcium | 560 | 139 |
| Amlodipine Besylate | Amlodipine Besylate | 556 | 140 |
| Levothyroxine Sodium | Levothyroxine Sodium | 529 | 103 |
| Omeprazole | Omeprazole | 528 | 113 |
| Lisinopril | Lisinopril | 391 | 97 |
| Furosemide | Furosemide | 354 | 97 |
| Oxycodone-Acetaminophen | Oxycodone Hcl/Acetaminophen | 326 | 41 |
| Carvedilol | Carvedilol | 319 | 93 |
| Losartan Potassium | Losartan Potassium | 294 | 75 |
| Tamsulosin Hcl | Tamsulosin Hcl | 286 | 76 |
| Metoprolol Succinate | Metoprolol Succinate | 272 | 71 |
| Trazodone Hcl | Trazodone Hcl | 271 | 56 |
| Metoprolol Tartrate | Metoprolol Tartrate | 236 | 53 |
| Metformin Hcl Er | Metformin Hcl | 231 | 52 |
| Metformin Hcl | Metformin Hcl | 228 | 57 |
| Sucralfate | Sucralfate | 220 | 59 |
| Glimepiride | Glimepiride | 219 | 43 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 219 | 60 |
| Tizanidine Hcl | Tizanidine Hcl | 211 | 37 |
| Clopidogrel | Clopidogrel Bisulfate | 209 | 55 |
| Famotidine | Famotidine | 208 | 50 |
| Cefdinir | Cefdinir | 205 | 170 |
| Farxiga | Dapagliflozin Propanediol | 205 | 32 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 193 | 61 |
| Sertraline Hcl | Sertraline Hcl | 185 | 35 |
| Methocarbamol | Methocarbamol | 182 | 44 |
| Montelukast Sodium | Montelukast Sodium | 177 | 46 |
| Pravastatin Sodium | Pravastatin Sodium | 176 | 36 |
| Tramadol Hcl | Tramadol Hcl | 171 | 29 |
| Pregabalin | Pregabalin | 165 | 24 |
| Quetiapine Fumarate | Quetiapine Fumarate | 165 | 23 |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 164 | 34 |
| Mirtazapine | Mirtazapine | 164 | 32 |
| Alprazolam | Alprazolam | 160 | 22 |
| Baclofen | Baclofen | 159 | 25 |
| Duloxetine Hcl | Duloxetine Hcl | 159 | 33 |
| Hydrochlorothiazide | Hydrochlorothiazide | 159 | 44 |
| Meloxicam | Meloxicam | 149 | 41 |
| Donepezil Hcl | Donepezil Hcl | 147 | 24 |
| Clonazepam | Clonazepam | 139 | 17 |
| Trulicity | Dulaglutide | 137 | 18 |
| Buspirone Hcl | Buspirone Hcl | 132 | 21 |
| Doxycycline Hyclate | Doxycycline Hyclate | 127 | 94 |
| Eliquis | Apixaban | 126 | 15 |
| Linzess | Linaclotide | 124 | 22 |
| Simvastatin | Simvastatin | 123 | 30 |
| Fluticasone Propionate | Fluticasone Propionate | 115 | 40 |
| Prednisone | Prednisone | 112 | 67 |
| Fluconazole | Fluconazole | 111 | 64 |
| Memantine Hcl | Memantine Hcl | 109 | 15 |
| Dicyclomine Hcl | Dicyclomine Hcl | 105 | 30 |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 105 | 31 |
| Ozempic | Semaglutide | 105 | 20 |
| Ondansetron Odt | Ondansetron | 101 | 49 |
| Escitalopram Oxalate | Escitalopram Oxalate | 97 | 28 |
| Lorazepam | Lorazepam | 96 | 17 |
| Pioglitazone Hcl | Pioglitazone Hcl | 96 | 21 |
| Allopurinol | Allopurinol | 95 | 33 |
| Citalopram Hbr | Citalopram Hydrobromide | 95 | 22 |
| Venlafaxine Hcl Er | Venlafaxine Hcl | 95 | 20 |
| Levetiracetam | Levetiracetam | 92 | 14 |
| Paroxetine Hcl | Paroxetine Hcl | 92 | 28 |
| Vitamin D2 | Ergocalciferol (Vitamin D2) | 92 | 16 |
| Amoxicillin | Amoxicillin | 90 | 46 |
| Ropinirole Hcl | Ropinirole Hcl | 89 | 12 |
| Triamcinolone Acetonide | Triamcinolone Acetonide | 89 | 45 |
| Fluoxetine Hcl | Fluoxetine Hcl | 86 | 14 |
| Hydralazine Hcl | Hydralazine Hcl | 85 | 22 |
| Topiramate | Topiramate | 85 | 13 |
| Ondansetron Hcl | Ondansetron Hcl | 84 | 22 |
| Torsemide | Torsemide | 83 | 17 |
| Diclofenac Sodium | Diclofenac Sodium | 82 | 27 |
| Finasteride | Finasteride | 82 | 21 |
| Ciprofloxacin Hcl | Ciprofloxacin Hcl | 80 | 69 |
| Ibuprofen | Ibuprofen | 79 | 20 |
| Hydroxyzine Hcl | Hydroxyzine Hcl | 77 | 36 |
| Alendronate Sodium | Alendronate Sodium | 76 | 15 |
| Tradjenta | Linagliptin | 76 | 16 |
| Ezetimibe | Ezetimibe | 75 | 22 |
| Xarelto | Rivaroxaban | 73 | 15 |
| Celecoxib | Celecoxib | 72 | 20 |
| Esomeprazole Magnesium | Esomeprazole Magnesium | 72 | 16 |
| Synthroid | Levothyroxine Sodium | 69 | 13 |
| Clonidine Hcl | Clonidine Hcl | 68 | 21 |
| Glipizide Er | Glipizide | 66 | 11 |
| Diazepam | Diazepam | 64 | suppressed |
| Divalproex Sodium | Divalproex Sodium | 62 | suppressed |
| Gemfibrozil | Gemfibrozil | 61 | 13 |
| Promethazine Hcl | Promethazine Hcl | 61 | 14 |
| Azithromycin | Azithromycin | 59 | 43 |
| Lovastatin | Lovastatin | 58 | 14 |
| Oxycodone Hcl | Oxycodone Hcl | 58 | suppressed |
| Isosorbide Mononitrate Er | Isosorbide Mononitrate | 57 | 12 |
| Levocetirizine Dihydrochloride | Levocetirizine Dihydrochloride | 56 | 33 |
| Aripiprazole | Aripiprazole | 54 | suppressed |
| Novolin R | Insulin Regular, Human | 54 | suppressed |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 53 | 17 |
| Mounjaro | Tirzepatide | 53 | suppressed |
| Levofloxacin | Levofloxacin | 51 | 36 |
| Oxybutynin Chloride | Oxybutynin Chloride | 51 | 12 |
| Amitriptyline Hcl | Amitriptyline Hcl | 50 | 12 |
| Azelastine Hcl | Azelastine Hcl | 50 | 30 |
| Irbesartan | Irbesartan | 50 | 11 |
| Januvia | Sitagliptin Phosphate | 50 | suppressed |
| Meclizine Hcl | Meclizine Hcl | 50 | 21 |
| Metolazone | Metolazone | 49 | 15 |
| Nitrofurantoin Mono-Macro | Nitrofurantoin Monohyd/M-Cryst | 48 | 29 |
| Oseltamivir Phosphate | Oseltamivir Phosphate | 48 | 48 |
| Anastrozole | Anastrozole | 47 | suppressed |
| Bupropion Xl | Bupropion Hcl | 47 | suppressed |
| Jardiance | Empagliflozin | 47 | 13 |
| Spironolactone | Spironolactone | 47 | 16 |
| Sulfamethoxazole-Trimethoprim | Sulfamethoxazole/Trimethoprim | 46 | 33 |
| Propranolol Hcl | Propranolol Hcl | 45 | 14 |
| Tresiba Flextouch U-200 | Insulin Degludec | 45 | 13 |
| Fenofibrate | Fenofibrate Nanocrystallized | 44 | suppressed |
| Zolpidem Tartrate | Zolpidem Tartrate | 43 | suppressed |
| Trelegy Ellipta | Fluticasone/Umeclidin/Vilanter | 42 | suppressed |
| Valsartan | Valsartan | 42 | suppressed |
| Oxybutynin Chloride Er | Oxybutynin Chloride | 41 | suppressed |
| Warfarin Sodium | Warfarin Sodium | 40 | suppressed |
| Benazepril Hcl | Benazepril Hcl | 38 | suppressed |
| Fenofibrate | Fenofibrate | 38 | 11 |
| Lansoprazole | Lansoprazole | 38 | suppressed |
| Tramadol Hcl-Acetaminophen | Tramadol Hcl/Acetaminophen | 38 | 12 |
| Cephalexin | Cephalexin | 36 | 21 |
| Diphenoxylate-Atropine | Diphenoxylate Hcl/Atropine | 36 | 24 |
| Amiodarone Hcl | Amiodarone Hcl | 35 | suppressed |
| Colchicine | Colchicine | 35 | 12 |
| Levemir | Insulin Detemir | 35 | suppressed |
| Glipizide | Glipizide | 34 | 11 |
| Nitroglycerin | Nitroglycerin | 34 | 15 |
| Primidone | Primidone | 34 | suppressed |
| Mupirocin | Mupirocin | 33 | 21 |
| Spiriva Respimat | Tiotropium Bromide | 33 | suppressed |
| Ketoconazole | Ketoconazole | 31 | 15 |
| Diltiazem 24hr Er (Cd) | Diltiazem Hcl | 30 | suppressed |
| Pramipexole Dihydrochloride | Pramipexole Di-Hcl | 30 | suppressed |
| Lactulose | Lactulose | 29 | 11 |
| Nystatin | Nystatin | 29 | 20 |
| Sildenafil Citrate | Sildenafil Citrate | 29 | suppressed |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 28 | suppressed |
| Lidocaine Hcl Viscous | Lidocaine Hcl | 28 | suppressed |
| Temazepam | Temazepam | 28 | suppressed |
| Acyclovir | Acyclovir | 26 | suppressed |
| Nifedipine Er | Nifedipine | 26 | suppressed |
| Valacyclovir | Valacyclovir Hcl | 26 | 12 |
| Butalbital-Acetaminophen-Caffe | Butalb/Acetaminophen/Caffeine | 25 | suppressed |
| Diltiazem 24hr Er (Xr) | Diltiazem Hcl | 25 | suppressed |
| Diltiazem Hcl | Diltiazem Hcl | 25 | suppressed |
| Oxcarbazepine | Oxcarbazepine | 25 | suppressed |
| Risperidone | Risperidone | 25 | suppressed |
| Verapamil Er | Verapamil Hcl | 25 | suppressed |
| Carisoprodol | Carisoprodol | 24 | suppressed |
| Morphine Sulfate | Morphine Sulfate | 24 | suppressed |
| Myrbetriq | Mirabegron | 24 | suppressed |
| Toujeo Solostar | Insulin Glargine,hum.Rec.Anlog | 24 | suppressed |
| Atenolol | Atenolol | 23 | suppressed |
| Estradiol | Estradiol | 23 | suppressed |
| Latanoprost | Latanoprost | 23 | suppressed |
| Neomycin-Polymyxin-Hc | Neomycin/Polymyxin B/Hydrocort | 22 | 20 |
| Clotrimazole-Betamethasone | Clotrimazole/Betamethasone Dip | 21 | 12 |
| Nortriptyline Hcl | Nortriptyline Hcl | 21 | suppressed |
| Acetaminophen-Codeine | Acetaminophen With Codeine | 20 | suppressed |
| Digoxin | Digoxin | 20 | suppressed |
| Fosinopril Sodium | Fosinopril Sodium | 20 | suppressed |
| Hydroxychloroquine Sulfate | Hydroxychloroquine Sulfate | 20 | suppressed |
| Testosterone Cypionate | Testosterone Cypionate | 20 | 12 |
| Amoxicillin-Clavulanate Potass | Amoxicillin/Potassium Clav | 19 | 17 |
| Chlorzoxazone | Chlorzoxazone | 19 | suppressed |
| Cyanocobalamin Injection | Cyanocobalamin (Vitamin B-12) | 19 | suppressed |
| Eszopiclone | Eszopiclone | 19 | suppressed |
| Phenobarbital | Phenobarbital | 19 | suppressed |
| Phenytoin Sodium Extended | Phenytoin Sodium Extended | 19 | suppressed |
| Ranolazine Er | Ranolazine | 19 | suppressed |
| Breo Ellipta | Fluticasone/Vilanterol | 18 | suppressed |
| Ramipril | Ramipril | 18 | suppressed |
| Anoro Ellipta | Umeclidinium Brm/Vilanterol Tr | 17 | suppressed |
| Bumetanide | Bumetanide | 17 | suppressed |
| Enalapril Maleate | Enalapril Maleate | 17 | suppressed |
| Risedronate Sodium | Risedronate Sodium | 17 | suppressed |
| Sumatriptan Succinate | Sumatriptan Succinate | 17 | suppressed |
| Tolterodine Tartrate Er | Tolterodine Tartrate | 17 | suppressed |
| Amlodipine Besylate-Benazepril | Amlodipine Besylate/Benazepril | 16 | suppressed |
| Budesonide-Formoterol Fumarate | Budesonide/Formoterol Fumarate | 16 | suppressed |
| Desvenlafaxine Succinate Er | Desvenlafaxine Succinate | 16 | suppressed |
| Humulin R | Insulin Regular, Human | 16 | suppressed |
| Symbicort | Budesonide/Formoterol Fumarate | 16 | suppressed |
| Cilostazol | Cilostazol | 15 | suppressed |
| Doxazosin Mesylate | Doxazosin Mesylate | 15 | suppressed |
| Entresto | Sacubitril/Valsartan | 15 | suppressed |
| Metronidazole | Metronidazole | 15 | 12 |
| Naproxen | Naproxen | 15 | suppressed |
| Novolog | Insulin Aspart | 15 | suppressed |
| Olmesartan Medoxomil | Olmesartan Medoxomil | 15 | suppressed |
| Triamterene-Hydrochlorothiazid | Triamterene/Hydrochlorothiazid | 15 | suppressed |
| Verapamil Sr | Verapamil Hcl | 15 | suppressed |
| Chlorhexidine Gluconate | Chlorhexidine Gluconate | 14 | suppressed |
| Megestrol Acetate | Megestrol Acetate | 14 | suppressed |
| Olanzapine | Olanzapine | 14 | suppressed |
| Rybelsus | Semaglutide | 14 | suppressed |
| Tresiba Flextouch U-100 | Insulin Degludec | 14 | suppressed |
| Victoza 3-Pak | Liraglutide | 14 | suppressed |
| Chlorthalidone | Chlorthalidone | 13 | suppressed |
| Clotrimazole | Clotrimazole | 13 | suppressed |
| Dextroamphetamine-Amphetamine | Dextroamphetamine/Amphetamine | 13 | suppressed |
| Galantamine Er | Galantamine Hbr | 13 | suppressed |
| Memantine Hcl Er | Memantine Hcl | 13 | suppressed |
| Novolog Mix 70-30 | Insulin Aspart Prot/Insuln Asp | 13 | suppressed |
| Tresiba | Insulin Degludec | 13 | suppressed |
| Venlafaxine Hcl | Venlafaxine Hcl | 13 | suppressed |
| Verapamil Hcl | Verapamil Hcl | 13 | suppressed |
| Basaglar Kwikpen U-100 | Insulin Glargine,hum.Rec.Anlog | 12 | suppressed |
| Dofetilide | Dofetilide | 12 | suppressed |
| Fenofibrate | Fenofibrate,micronized | 12 | suppressed |
| Fluvoxamine Maleate | Fluvoxamine Maleate | 12 | suppressed |
| Ipratropium Bromide | Ipratropium Bromide | 12 | suppressed |
| Jentadueto | Linagliptin/Metformin Hcl | 12 | suppressed |
| Levemir Flexpen | Insulin Detemir | 12 | suppressed |
| Morphine Sulfate Er | Morphine Sulfate | 12 | suppressed |
| Rivastigmine | Rivastigmine | 12 | suppressed |
| Trandolapril | Trandolapril | 12 | suppressed |
| Ventolin Hfa | Albuterol Sulfate | 12 | suppressed |
| Vraylar | Cariprazine Hcl | 12 | suppressed |
| Alprazolam Xr | Alprazolam | 11 | suppressed |
| Bisoprolol Fumarate | Bisoprolol Fumarate | 11 | suppressed |
| Budesonide | Budesonide | 11 | suppressed |
| Carbamazepine | Carbamazepine | 11 | suppressed |
| Chlorpromazine Hcl | Chlorpromazine Hcl | 11 | suppressed |
| Cimetidine | Cimetidine | 11 | suppressed |
| Constulose | Lactulose | 11 | suppressed |
| Cyclosporine | Cyclosporine | 11 | suppressed |
| Fluticasone-Salmeterol | Fluticasone Propion/Salmeterol | 11 | suppressed |
| Prednisolone Acetate | Prednisolone Acetate | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $278.11 · 14 records | Salix Pharmaceuticals, a division of Bausch Health US, LLC | EVENITY, NUZYRA, REXULTI, Sunosi, Wegovy, XIFAXAN | 3 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- How do you evaluate evidence when you have a financial relationship with Novo Nordisk Inc?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error